Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy

被引:21
作者
Park, Chul-Kee [1 ]
Lee, Se-Hoon [2 ,4 ]
Han, Jung Ho [1 ]
Kim, Chae-Yong [1 ]
Kim, Dong-Wan [2 ,4 ]
Paek, Sun Ha [1 ,4 ]
Kim, Dong Gyu [1 ]
Heo, Dae Seog [2 ,4 ]
Kim, Il Han [3 ,4 ]
Jung, Hee-Won [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Radiat Oncol, Seoul 110744, South Korea
[4] Seoul Natl Univ Hosp, Canc Res Inst, Seoul 110744, South Korea
关键词
RADIATION-THERAPY; ANAPLASTIC ASTROCYTOMA; BRAIN METASTASES; VINCRISTINE PCV; CLASSIFICATION; SURVIVAL; TUMORS; OLIGODENDROGLIOMA; GLIOBLASTOMA; TEMOZOLOMIDE;
D O I
10.1186/1471-2407-9-450
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We evaluated the hierarchical risk groups for the estimated survival of WHO grade III glioma patients using recursive partitioning analysis (RPA). To our knowledge, this is the first study to address the results of RPA specifically for WHO grade III gliomas. Methods: A total of 133 patients with anaplastic astrocytoma (AA, n = 56), anaplastic oligodendroglioma (AO, n = 67), or anaplastic oligoastrocytoma (AOA, n = 10) were included in the study. These patients were treated with either radiotherapy alone or radiotherapy followed by PCV chemotherapy after surgery. Five prognostic factors, including histological subsets, age, performance status, extent of resection, and treatment modality were incorporated into the RPA. The final nodes of RPA were grouped according to their survival times, and the Kaplan-Meier graphs are presented as the final set of prognostic groups. Results: Four risk groups were defined based on the clinical prognostic factors excluding age, and split variables were all incorporated into the RPA. Survival analysis showed significant differences in mean survival between the different groups: 163.4 months (95% CI: 144.9-182.0), 109.5 months (86.7-132.4), 66.6 months (50.8-82.4), and 27.7 months (16.3-39.0), respectively, from the lowest to the highest risk group (p = 0.00). Conclusion: The present study shows that RPA grouping with clinical prognostic factors can successfully predict the survival of patients with WHO grade III glioma.
引用
收藏
页数:7
相关论文
共 29 条
[1]  
[Anonymous], 2008, STAT REP PRIM BRAIN
[2]  
BENT MJ, 2006, J CLIN ONCOL, V24, P2715
[3]   Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 [J].
Cairncross, Gregory ;
Berkey, Brian ;
Shaw, Edward ;
Jenkins, Robert ;
Scheithauer, Bernd ;
Brachman, David ;
Buckner, Jan ;
Fink, Karen ;
Souhami, Luis ;
Laperierre, Normand ;
Mehta, Minesh ;
Curran, Walter .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) :2707-2714
[4]   CEREBRAL OLIGODENDROGLIOMA - PROGNOSTIC FACTORS AND LIFE-HISTORY [J].
CELLI, P ;
NOFRONE, I ;
PALMA, L ;
CANTORE, G ;
FORTUNA, A .
NEUROSURGERY, 1994, 35 (06) :1018-1034
[5]   RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH ADVANCED CANCER [J].
Chow, Edward ;
Abdolell, Mohamed ;
Panzarella, Tony ;
Harris, Kristin ;
Bezjak, Andrea ;
Warde, Padraig ;
Tannock, Ian .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (04) :1169-1176
[6]   Prognostic factors for anaplastic astrocytomas [J].
Compostella, Alessia ;
Tosoni, Alicia ;
Blatt, Valeria ;
Franceschi, Enrico ;
Brandes, Alba A. .
JOURNAL OF NEURO-ONCOLOGY, 2007, 81 (03) :295-303
[7]   RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS [J].
CURRAN, WJ ;
SCOTT, CB ;
HORTON, J ;
NELSON, JS ;
WEINSTEIN, AS ;
FISCHBACH, AJ ;
CHANG, CH ;
ROTMAN, M ;
ASBELL, SO ;
KRISCH, RE ;
NELSON, DF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (09) :704-710
[8]   Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials [J].
Gaspar, L ;
Scott, C ;
Rotman, M ;
Asbell, S ;
Phillips, T ;
Wasserman, T ;
McKenna, WG ;
Byhardt, R .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (04) :745-751
[9]   The use of recursive partitioning analysis grouping in patients with brain metastases from non-small-cell lung cancer [J].
Guelbas, Huelya ;
Erkal, Haldun Suekrue ;
Serin, Meltem .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (04) :193-196
[10]   ADJUVANT THERAPY WITH DIBROMODULCITOL AND BCNU INCREASES SURVIVAL OF ADULTS WITH MALIGNANT GLIOMAS [J].
HILDEBRAND, J ;
SAHMOUD, T ;
MIGNOLET, F ;
BRUCHER, JM ;
AFRA, D ;
GARFIELD, J ;
MCDONALD, H ;
PUNT, J ;
SOKAL, M ;
DETRIBOLET, N ;
REGLI, L ;
FAVRE, J ;
VERNET, O ;
DARCELMENAULT, F ;
HASSEL, MB ;
GUEGAN, Y ;
KOCSIS, B ;
MAYER, A ;
SIPOS, L ;
BROTCHI, J ;
DEWITTE, O ;
REGNIER, R ;
CHATEL, M ;
FRENAY, M ;
HERY, M ;
MAAT, B ;
HAFERKAMP, G ;
KARSTENS, JH ;
SAMII, M ;
DIETZ, H .
NEUROLOGY, 1994, 44 (08) :1479-1483